If You Invested in Xeris Biopharma Holdings (XERS)

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) is a biopharmaceutical company that develops and commercializes products across a range of therapeutic areas, with a focus on endocrine and neurological conditions. According to company disclosures, Xeris markets three FDA-approved therapies and is advancing additional product candidates and formulation platforms. The company is headquartered in Chicago, Illinois.

Xeris’ commercial portfolio centers on three branded products: Recorlev, Gvoke, and Keveyis. Recorlev (levoketoconazole) is approved for the treatment of endogenous Cushing’s syndrome in adult patients for whom surgery is not an option or has not been curative. It is described as an adrenal steroidogenesis inhibitor and a purified enantiomer of ketoconazole, and is protected by multiple patents listed in the U.S. Food and Drug Administration’s Orange Book. The company has highlighted Recorlev as a key growth driver and has expanded its intellectual property protection for the product through additional Orange Book-listed patents.

Gvoke is described by Xeris as a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. In company communications, Gvoke is also identified as a gastrointestinal motility inhibitor when used as a diagnostic aid during radiologic examinations. Xeris has entered into a partnership with American Regent, Inc. for Gvoke VialDx, a concentrated, ready-to-dilute liquid glucagon indicated as a diagnostic aid to temporarily inhibit movement of the gastrointestinal tract in adult patients. Under that agreement, Xeris is responsible for product supply while American Regent manages commercialization of Gvoke VialDx in the United States.

Keveyis is characterized by Xeris as a proven therapy for primary periodic paralysis, a rare neuromuscular condition. Together, Recorlev, Gvoke, and Keveyis form the company’s core commercial portfolio. Xeris reports product revenue from each of these brands, and its public financial updates discuss trends in patient demand, net revenue, and product shipments across these therapies.

Pipeline and Technology Platforms

Beyond its marketed products, Xeris is advancing a pipeline of development programs. The company identifies XP-8121 as its lead pipeline asset. XP-8121 is described as a Phase 3–ready, once-weekly subcutaneous injection for hypothyroidism. In public statements, Xeris explains that XP-8121 is an investigational, ready-to-use liquid formulation of levothyroxine sodium designed for once-weekly subcutaneous injection using its proprietary XeriSol technology. The company indicates that by avoiding the gastrointestinal tract, XP-8121 is intended to address limitations associated with oral levothyroxine therapy.

Xeris also references multiple early-stage programs that use its proprietary formulation platforms, XeriSol and XeriJect, in collaboration with partners. These platforms are described as enabling the development of difficult-to-formulate drugs into subcutaneous injections. In addition to the XP-8121 patent allowance from the U.S. Patent and Trademark Office, Xeris has stated that it is pursuing additional layers of intellectual property protection in the levothyroxine technology space.

Intellectual Property and Regulatory Position

The company emphasizes the role of intellectual property in supporting its commercial and pipeline assets. For Recorlev, Xeris has disclosed that the product is protected by multiple patents listed in the FDA’s Orange Book, including a patent titled “Methods of Treating Disease with Levoketoconazole,” which covers therapeutic uses designed to minimize certain drug–drug interactions. The company notes that Recorlev is not classified as a controlled substance by the U.S. Drug Enforcement Administration.

For XP-8121, Xeris has reported a Notice of Allowance from the U.S. Patent and Trademark Office for claims specific to the XP-8121 formulation. The company has also described strengthening its intellectual property portfolio with a composition-of-matter patent for XP-8121 and a new Orange Book-listed patent for Recorlev, reinforcing long-term protection across both commercial and pipeline assets.

Business Focus and Growth Orientation

In its public communications and SEC filings, Xeris describes itself as a growth-oriented or fast-growing biopharmaceutical company. Management commentary highlights revenue growth across Recorlev, Gvoke, and Keveyis, as well as increasing patient demand and investments in commercial infrastructure, particularly for Recorlev. The company has discussed achieving positive Adjusted EBITDA in multiple quarters and has provided long-term financial targets and strategic vision at its Analyst and Investor Day.

Xeris’ reported results and guidance emphasize total revenue growth, changes in product mix, and the contribution of royalty, contract, and other revenue associated with partnered products such as Gvoke VialDx. The company also notes increased research and development spending to support XP-8121 and the ongoing development of its technology platforms and partnerships, as well as selling, general, and administrative expenses related to personnel and commercial expansion.

Stock and Regulatory Filings

Xeris Biopharma Holdings, Inc. trades on the Nasdaq under the ticker symbol XERS. The company files periodic and current reports with the U.S. Securities and Exchange Commission, including Form 8-K reports that furnish press releases on quarterly results and operational highlights. These filings provide additional detail on revenue by product, operating expenses, net income or loss, and non-GAAP measures such as Adjusted EBITDA, along with management’s discussion of business performance.

Key Therapeutic Areas

• Endogenous Cushing’s syndrome and hypercortisolemia: addressed by Recorlev, an adrenal steroidogenesis inhibitor approved for adult patients for whom surgery is not an option or has not been curative.
• Severe hypoglycemia: addressed by Gvoke, a ready-to-use liquid glucagon product.
• Diagnostic radiology support: addressed by Gvoke when used as a gastrointestinal motility inhibitor and by Gvoke VialDx as a diagnostic aid during radiologic examinations in adult patients.
• Primary periodic paralysis: addressed by Keveyis, which Xeris describes as a proven therapy for this rare condition.
• Hypothyroidism: targeted by XP-8121, an investigational once-weekly subcutaneous levothyroxine formulation.

FAQs